187 related articles for article (PubMed ID: 8526382)
1. Prospective study on the diagnosis and prognosis of lung cancer by using new simultaneously observed seromarkers.
Zhang Q; Ren H; Wang B
Ann N Y Acad Sci; 1995 Sep; 768():337-40. PubMed ID: 8526382
[No Abstract] [Full Text] [Related]
2. Serum tumour markers in lung cancer.
Hansen M
Scand J Clin Lab Invest Suppl; 1991; 206():93-101. PubMed ID: 1658919
[No Abstract] [Full Text] [Related]
3. Elastase levels in small and non-small cell lung carcinoma.
Güner G; Kirkali G; Baskin Y; Karlikaya C; Akkoçlu A
Biochem Soc Trans; 1993 Aug; 21 ( Pt 3)(3):305S. PubMed ID: 8224451
[No Abstract] [Full Text] [Related]
4. [T1-2N0M0-stage lung cancer, its diagnosis and treatment results].
Perel'man MI; Denisov LE; Odintsov SV
Ter Arkh; 1989; 61(7):128-31. PubMed ID: 2555930
[No Abstract] [Full Text] [Related]
5. Soluble interleukin 2 receptor (sIL2R) in monitoring advanced lung cancer during chemotherapy.
Brunetti G; Bossi A; Baiardi P; Jedrychowska I; Pozzi U; Bacchella L; Bernardo G
Lung Cancer; 1999 Jan; 23(1):1-9. PubMed ID: 10100141
[TBL] [Abstract][Full Text] [Related]
6. Tissue polypeptide antigen in bronchogenic carcinoma.
Zatloukal P; Glagolicová A; Linhart M; Sebes A; Hencl P; Mĕricka O
Neoplasma; 1993; 40(5):301-3. PubMed ID: 8272159
[TBL] [Abstract][Full Text] [Related]
7. The serum ferritin concentration is a significant prognostic indicator of survival in primary lung cancer.
Milman N; Pedersen LM
Oncol Rep; 2002; 9(1):193-8. PubMed ID: 11748482
[TBL] [Abstract][Full Text] [Related]
8. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
9. Serum pleiotrophin could be an early indicator for diagnosis and prognosis of non-small cell lung cancer.
Du ZY; Shi MH; Ji CH; Yu Y
Asian Pac J Cancer Prev; 2015; 16(4):1421-5. PubMed ID: 25743809
[TBL] [Abstract][Full Text] [Related]
10. CYFRA 21-1 enzyme-linked immunosorbent assay. Evaluation as a tumor marker in non-small cell lung cancer.
Lai RS; Hsu HK; Lu JY; Ger LP; Lai NS
Chest; 1996 Apr; 109(4):995-1000. PubMed ID: 8635383
[TBL] [Abstract][Full Text] [Related]
11. [Pulmonary carcinoma. The effect of assessing histologic type on the prognosis].
Santangelo A; Turra G; Fantini A; Morgutti L
Minerva Med; 1989 Jul; 80(7):689-91. PubMed ID: 2550850
[No Abstract] [Full Text] [Related]
12. Clinical usefulness of serum cytokeratin 19 fragment as a tumor marker for lung cancer.
Maeda Y; Segawa Y; Takigawa N; Takata I; Fujimoto N
Intern Med; 1996 Oct; 35(10):764-71. PubMed ID: 8933183
[TBL] [Abstract][Full Text] [Related]
13. The staging of lung cancer.
Little AG; DeMeester TR; MacMahon H
Semin Oncol; 1983 Mar; 10(1):56-70. PubMed ID: 6301065
[No Abstract] [Full Text] [Related]
14. Evaluation of CYFRA 21-1 in malignant and benign pleural effusions.
Toumbis M; Rasidakis A; Passalidou E; Kalomenidis J; Alchanatis M; Orphanidou D; Jordanoglou J
Anticancer Res; 1996; 16(4A):2101-4. PubMed ID: 8712750
[TBL] [Abstract][Full Text] [Related]
15. Serum levels of neuron-specific enolase, carbohydrate antigen 19-9 and carbohydrate antigen 125 in carcinoma of the lung.
Oktay G; Güner G; Karlikaya C; Akkoçlu A
Biochem Soc Trans; 1995 May; 23(2):211S. PubMed ID: 7672232
[No Abstract] [Full Text] [Related]
16. Elevated plasma thymosin-alpha1 levels in lung cancer patients.
Sasaki H; Fujii Y; Masaoka A; Yamakawa Y; Fukai I; Kiriyama M; Saito Y; Matsui H
Eur J Cardiothorac Surg; 1997 Dec; 12(6):885-91. PubMed ID: 9489875
[TBL] [Abstract][Full Text] [Related]
17. Serum levels of vascular endothelial growth factor dependent on the stage progression of lung cancer.
Matsuyama W; Hashiguchi T; Mizoguchi A; Iwami F; Kawabata M; Arimura K; Osame M
Chest; 2000 Oct; 118(4):948-51. PubMed ID: 11035661
[TBL] [Abstract][Full Text] [Related]
18. Circulating U2 small nuclear RNA fragments as a diagnostic and prognostic biomarker in lung cancer patients.
Köhler J; Schuler M; Gauler TC; Nöpel-Dünnebacke S; Ahrens M; Hoffmann AC; Kasper S; Nensa F; Gomez B; Hahnemann M; Breitenbuecher F; Cheufou D; Özkan F; Darwiche K; Hoiczyk M; Reis H; Welter S; Eberhardt WE; Eisenacher M; Teschler H; Stamatis G; Schmiegel W; Hahn SA; Baraniskin A
J Cancer Res Clin Oncol; 2016 Apr; 142(4):795-805. PubMed ID: 26687686
[TBL] [Abstract][Full Text] [Related]
19. Biomarkers and IL-2R in lung cancer.
Marino P; Preatoni A; Fonticoli L; Parodi M; Tarolo GL
Recenti Prog Med; 1990 Nov; 81(11):702-4. PubMed ID: 1962891
[TBL] [Abstract][Full Text] [Related]
20. Pro-gastrin-releasing peptide (ProGRP)--a useful marker in small cell lung carcinomas.
Stieber P; Dienemann H; Schalhorn A; Schmitt UM; Reinmiedl J; Hofmann K; Yamaguchi K
Anticancer Res; 1999; 19(4A):2673-8. PubMed ID: 10470218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
